cd 437 has been researched along with Acne in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arlabosse, JM; Bouix-Peter, C; Chambon, S; Chantalat, L; Daver, S; Dumais, L; Duvert, G; Feret, A; Ouvry, G; Pascau, J; Portal, T; Raffin, C; Rodeville, N; Soulet, C; Tabet, S; Talano, S; Thoreau, E | 1 |
1 other study(ies) available for cd 437 and Acne
Article | Year |
---|---|
Structure-based design of Trifarotene (CD5789), a potent and selective RARĪ³ agonist for the treatment of acne.
Topics: Acne Vulgaris; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoids; Structure-Activity Relationship | 2018 |